Rigel Pharmaceuticals (RIGL) EBT Margin (2010 - 2026)

Rigel Pharmaceuticals' EBT Margin history runs 16 years deep, the most recent figure standing at 19.82% for Q1 2026.

• In Q1 2026, EBT Margin fell 176.0% year-over-year to 19.82%; the TTM figure through Mar 2026 stood at 40.69% (up 2192.0% YoY), while the FY2025 annual figure was 41.4%, up 3115.0% from the prior year.
• EBT Margin was 19.82% for Q1 2026 at Rigel Pharmaceuticals, down from 32.54% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 58.99% in Q2 2025 to a low of 164.0% in Q1 2022.
• Historically, EBT Margin has averaged 11.48% across 5 years, with a median of 2.06% in 2023.
• Biggest YoY gain for EBT Margin was 11396 bps in 2022; the steepest drop was 21494 bps in 2022.
• A 5-year view of EBT Margin shows it stood at 2.73% in 2022, then declined by 25 bps to 2.06% in 2023, then jumped by 1184 bps to 26.43% in 2024, then rose by 23 bps to 32.54% in 2025, then plunged by 39 bps to 19.82% in 2026.
• The last three EBT Margin figures came in at 19.82% (Q1 2026), 32.54% (Q4 2025), and 39.76% (Q3 2025), per Business Quant data.